Payment overview · 2025
General Payments
$372.51
19 reported records · 8 companies
Healthcare provider profile · identity verified
Jon F Bode, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRENHAM, TX · NPI 1124090725
Verified facts
What the public records show
CMS Open Payments records show Jon F Bode, MD received $372.51 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.47 | 46.8% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $35.23 | 9.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.68 | 8.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.87 | 8.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.72 | 8.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.63 | 7.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.80 | 6.7% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $19.11 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $372.51 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.97 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.68 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $19.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 75 |
| Gabapentin | Gabapentin | 210 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 47 |
| Losartan Potassium | Losartan Potassium | 157 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 46 |
| Lisinopril | Lisinopril | 141 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 37 |
| Eliquis | Apixaban | 112 | 32 |
| Omeprazole | Omeprazole | 105 | 30 |
| Metformin Hcl | Metformin Hcl | 104 | 30 |
| Carvedilol | Carvedilol | 88 | 29 |
| Meloxicam | Meloxicam | 86 | 20 |
| Prednisone | Prednisone | 85 | 42 |
| Metformin Hcl Er | Metformin Hcl | 83 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 22 |
| Simvastatin | Simvastatin | 82 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 24 |
| Furosemide | Furosemide | 78 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 25 |
| Tramadol Hcl | Tramadol Hcl | 76 | 19 |
| Allopurinol | Allopurinol | 75 | 21 |
| Glimepiride | Glimepiride | 71 | 16 |
| Celecoxib | Celecoxib | 66 | 19 |
| Mirtazapine | Mirtazapine | 64 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 21 |
| Potassium Chloride | Potassium Chloride | 57 | 21 |
| Jardiance | Empagliflozin | 56 | 11 |
| Ozempic | Semaglutide | 56 | 14 |
| Alendronate Sodium | Alendronate Sodium | 55 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 19 |
| Donepezil Hcl | Donepezil Hcl | 53 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 52 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 13 |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Pregabalin | Pregabalin | 38 | 11 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 14 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 11 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | 11 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 11 |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $372.51 · 19 records | Novo Nordisk Inc | AIRSUPRA, Dexcom G6 Transmitter, Doc Band, GEMTESA, Ozempic, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error